Abstract
Although asthma defines a syndrome associated with airway inflammation, heterogeneity exists concerning the type of inflammation that modulates airway hyperresponsiveness. Compelling evidence suggests that common triggers of asthma exacerbations are preferentially mediated by neutrophilic airway inflammation. Currently, there exists no therapeutic approach that uniquely targets neutrophils in asthma. Given that neutrophilic airway inflammation seems to be steroid insensitive and given recent advances in neutrophil biology, exciting opportunities may lead to targeted therapy that focuses on the activation state of neutrophils rather than neutrophil number as a means to improve asthma outcomes in difficult to treat patients.
Original language | English (US) |
---|---|
Pages (from-to) | 629-638 |
Number of pages | 10 |
Journal | Immunology and Allergy Clinics of North America |
Volume | 38 |
Issue number | 4 |
DOIs | |
State | Published - Nov 2018 |
All Science Journal Classification (ASJC) codes
- Immunology and Allergy
- Immunology
Keywords
- Airway remodeling
- Immunocyte
- Intrinsic asthma
- Irreversible airway obstruction
- Severe asthma
- Steroid insensitivity